ATE314471T1 - Menschliche toll homologen - Google Patents

Menschliche toll homologen

Info

Publication number
ATE314471T1
ATE314471T1 AT98953294T AT98953294T ATE314471T1 AT E314471 T1 ATE314471 T1 AT E314471T1 AT 98953294 T AT98953294 T AT 98953294T AT 98953294 T AT98953294 T AT 98953294T AT E314471 T1 ATE314471 T1 AT E314471T1
Authority
AT
Austria
Prior art keywords
human toll
pro286
pro285
toll homologue
pro358
Prior art date
Application number
AT98953294T
Other languages
English (en)
Inventor
Audrey Goddard
Paul J Godowski
Austin L Gurney
Melanie R Mark
Ruey-Bing Yang
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27535565&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE314471(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genentech Inc filed Critical Genentech Inc
Application granted granted Critical
Publication of ATE314471T1 publication Critical patent/ATE314471T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Organic Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
AT98953294T 1997-10-17 1998-10-07 Menschliche toll homologen ATE314471T1 (de)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US6225097P 1997-10-17 1997-10-17
US6531197P 1997-11-13 1997-11-13
US8332298P 1998-04-28 1998-04-28
US10541398A 1998-06-26 1998-06-26
US9086398P 1998-06-26 1998-06-26
PCT/US1998/021141 WO1999020756A2 (en) 1997-10-17 1998-10-07 Human toll homologues

Publications (1)

Publication Number Publication Date
ATE314471T1 true ATE314471T1 (de) 2006-01-15

Family

ID=27535565

Family Applications (3)

Application Number Title Priority Date Filing Date
AT07020354T ATE463502T1 (de) 1997-10-17 1998-10-07 Menschliche toll-homologe
AT05023238T ATE381574T1 (de) 1997-10-17 1998-10-07 Menschliche toll-homologe
AT98953294T ATE314471T1 (de) 1997-10-17 1998-10-07 Menschliche toll homologen

Family Applications Before (2)

Application Number Title Priority Date Filing Date
AT07020354T ATE463502T1 (de) 1997-10-17 1998-10-07 Menschliche toll-homologe
AT05023238T ATE381574T1 (de) 1997-10-17 1998-10-07 Menschliche toll-homologe

Country Status (11)

Country Link
EP (3) EP1887014B1 (de)
JP (3) JP4319348B2 (de)
AT (3) ATE463502T1 (de)
AU (1) AU1070399A (de)
CA (1) CA2305385C (de)
DE (3) DE69833014T2 (de)
DK (3) DK1650219T3 (de)
ES (2) ES2298905T3 (de)
IL (4) IL135345A0 (de)
PT (2) PT1887014E (de)
WO (1) WO1999020756A2 (de)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7696327B1 (en) 1997-10-17 2010-04-13 Genentech, Inc. Antibodies to human Toll homologues
DK0980429T3 (da) * 1997-05-07 2007-04-10 Schering Corp Human Toll-lignende receptorproteiner, beslægtede reagenser og fremgangsmåder
AU2001264889B2 (en) * 1997-05-07 2006-06-29 Schering Corporation Human receptor proteins; related reagents and methods
US20030032090A1 (en) 1997-05-07 2003-02-13 Schering Corporation, A New Jersey Corporation Human receptor proteins; related reagents and methods
US6303321B1 (en) 1999-02-11 2001-10-16 North Shore-Long Island Jewish Research Institute Methods for diagnosing sepsis
MXPA02011618A (es) * 2000-05-25 2003-03-10 Schering Corp Proteinas de receptor de humano, reactivos y metodos relacionados.
JP2005500806A (ja) 2000-09-15 2005-01-13 コーリー ファーマシューティカル ゲーエムベーハー ＣｐＧに基づく免疫アゴニスト／免疫アンタゴニストの高スループットスクリーニングのためのプロセス
US7304034B2 (en) 2001-05-15 2007-12-04 The Feinstein Institute For Medical Research Use of HMGB fragments as anti-inflammatory agents
US7220723B2 (en) 2001-05-15 2007-05-22 The Feinstein Institute For Medical Research Inhibitors of the interaction between HMGB polypeptides and toll-like receptor 2 as anti-inflammatory agents
EP1293566A1 (de) * 2001-09-17 2003-03-19 Societe Des Produits Nestle S.A. Ein löslicher Toll-ähnlicher Rezeptor
EP2366389A1 (de) * 2002-04-08 2011-09-21 Takeda Pharmaceutical Company Limited Therapeutikum zur Prävention schwerer Blutvergiftung
US8183350B2 (en) 2002-05-04 2012-05-22 Acorda Therapeutics, Inc. Compositions and methods for promoting neuronal outgrowth
CN1829730A (zh) 2002-11-12 2006-09-06 贝克顿迪金森公司 使用生物标记谱诊断脓毒或者sirs
AU2003295649A1 (en) * 2002-11-22 2004-06-18 Nuvelo,Inc. Methods of therapy and diagnosis
WO2004094671A2 (en) * 2003-04-22 2004-11-04 Coley Pharmaceutical Gmbh Methods and products for identification and assessment of tlr ligands
ES2636653T3 (es) * 2003-05-16 2017-10-06 Acorda Therapeutics, Inc. Mutantes degradantes del proteoglucano para el tratamiento del SNC
US7959914B2 (en) 2003-05-16 2011-06-14 Acorda Therapeutics, Inc. Methods of reducing extravasation of inflammatory cells
US7696169B2 (en) 2003-06-06 2010-04-13 The Feinstein Institute For Medical Research Inhibitors of the interaction between HMGB polypeptides and toll-like receptor 2 as anti-inflammatory agents
US8163506B2 (en) 2003-06-17 2012-04-24 Meiji Co., Ltd. Use of toll-like receptor-expressing cells
JP4562123B2 (ja) * 2003-06-17 2010-10-13 明治乳業株式会社 Ｔｏｌｌ様レセプター強制発現細胞の利用
CN1878793A (zh) 2003-09-11 2006-12-13 鉴定医疗有限公司 拮抗hmgb1的单克隆抗体
WO2005112986A2 (en) 2004-05-18 2005-12-01 Acorda Therapeutics, Inc. Purifying chondroitinase and stable formulations thereof
DK1773872T3 (en) * 2004-05-21 2017-05-08 Uab Res Found VARIABLE Lymphocyte Receptors, Associated Polypeptides and Nucleic Acids, and Uses thereof
EP1869463A4 (de) 2005-04-15 2010-05-05 Becton Dickinson Co Sepsisdiagnose
WO2007038548A2 (en) 2005-09-26 2007-04-05 Acorda Therapeutics, Inc. Compositions and methods of using chondroitinase abci mutants
JP5199878B2 (ja) 2005-10-27 2013-05-15 セントカー・インコーポレーテツド Ｔｏｌｌ様受容体３モジュレーター、方法および用途
CA2649387A1 (en) * 2006-04-19 2008-03-27 Genentech, Inc. Novel gene disruptions, compositions and methods relating thereto
AU2007307736C1 (en) 2006-10-10 2014-04-10 Acorda Therapeutics, Inc. Compositions and methods of using chondroitinase ABCI mutants
WO2009123737A2 (en) 2008-04-03 2009-10-08 Becton, Dickinson And Company Advanced detection of sepsis
JP6131046B2 (ja) 2010-01-27 2017-05-17 武田薬品工業株式会社 抗癌剤により誘発される末梢神経障害を抑制する化合物
CN117534753B (zh) * 2023-12-07 2024-05-10 北京博奥森生物技术有限公司 一种诱导高性能NF-κB多克隆抗体多肽及其应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
EP0308936B1 (de) 1987-09-23 1994-07-06 Bristol-Myers Squibb Company Antikörper-Heterokonjugate zur Töting von HIV-infizierten Zellen
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
CA2062795A1 (en) 1989-06-29 1990-12-30 Michael W. Fanger Bispecific reagents for aids therapy
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
EP0814159B1 (de) 1990-08-29 2005-07-27 GenPharm International, Inc. Transgene Mäuse fähig zur Produktion heterologer Antikörper
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
JPH06507398A (ja) 1991-05-14 1994-08-25 リプリジェン　コーポレーション Ｈｉｖ感染治療のための異種複合抗体
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
DK0980429T3 (da) * 1997-05-07 2007-04-10 Schering Corp Human Toll-lignende receptorproteiner, beslægtede reagenser og fremgangsmåder
PT1386931E (pt) * 1998-03-25 2006-09-29 Genentech Inc Homologo de neurotrimina humana

Also Published As

Publication number Publication date
AU1070399A (en) 1999-05-10
CA2305385C (en) 2013-05-21
PT1887014E (pt) 2010-07-05
ATE463502T1 (de) 2010-04-15
DK1887014T3 (da) 2010-08-02
ES2343210T3 (es) 2010-07-26
WO1999020756A3 (en) 1999-09-10
JP2009131265A (ja) 2009-06-18
JP4319348B2 (ja) 2009-08-26
DE69838888T2 (de) 2008-12-11
DK1650219T3 (da) 2008-05-05
JP5027105B2 (ja) 2012-09-19
PT1650219E (pt) 2008-03-31
JP2012105662A (ja) 2012-06-07
EP1025227B1 (de) 2005-12-28
ES2298905T3 (es) 2008-05-16
DK1025227T3 (da) 2006-05-01
IL221367A (en) 2015-06-30
ATE381574T1 (de) 2008-01-15
DE69833014D1 (de) 2006-02-02
DE69833014T2 (de) 2006-08-10
WO1999020756A2 (en) 1999-04-29
IL135345A0 (en) 2001-05-20
EP1650219A1 (de) 2006-04-26
EP1025227A2 (de) 2000-08-09
IL135345A (en) 2007-06-03
IL180967A0 (en) 2007-07-04
DE69841607D1 (de) 2010-05-20
EP1650219B1 (de) 2007-12-19
CA2305385A1 (en) 1999-04-29
IL180967A (en) 2012-09-24
JP5425244B2 (ja) 2014-02-26
JP2002526028A (ja) 2002-08-20
DE69838888D1 (de) 2008-01-31
EP1887014A1 (de) 2008-02-13
EP1887014B1 (de) 2010-04-07

Similar Documents

Publication Publication Date Title
ATE381574T1 (de) Menschliche toll-homologe
HK1211618A1 (en) Nogo receptor binding protein nogo
HK1027577A1 (en) Selection of proteins using rna-protein fusions
ATE329028T1 (de) Nl3 tie rezeptortyrosinekinase ligandhomologe
DE69813158T2 (de) Assays zur Bestimmung von Proteinfragmenten in biologischen Medien
ATE394484T1 (de) Smad 6 und dessen anwendungen
PT868519E (pt) Diagnostico e tratamento de disturbios relacionados com aur-1 e/ou aur-2
EP0816498A3 (de) Exzitatorische Aminosäure Rezeptor-Protein und verwante Nukleinsäure
WO2000034294A3 (en) Tumor necrosis factor receptor homologue-1 ('trh1')
DE59712604D1 (de) Mittel zur identifizierung und therapie metastasierender tumore

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1025227

Country of ref document: EP

RZN Patent revoked